Stock Taper
SCREENER COMPARE ANY 2 STOCKS
VIR
VIR BIOTECHNOLOGY, INC.
NASDAQ
$10.83
▼ DOWN 4.24% (-0.48)

KEY STATISTICS

Market Cap$1.83 B
52w High$11.66
52w Low$4.75
Dividend Yield—
Frequency—
P/E-5.82
Volume1.84M
Shares Out.168.65M

COMPANY

LEADERSHIP

Marianne De Backer
CHIEF EXECUTIVE
Marianne De Backer

COMPENSATION 2026

Salary$950,000
Stock Awards$2,296,800
Incentive Plan Pay$1,002,750
All Other Comp.$77,135
Total$7,834,045

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 11, 2019
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
367

PRICE TARGET

Target High$25.00
Target Low$20.00
Target Median$22.50
Target Consensus$22.50

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.$865.13K
NOV
4
WED

PRICE

$10.83 ▼ DOWN 4.24% (−$0.48)
$10.80$11.00$11.20$11.409:31 AM10:36 AM11:40 AM12:45 PM1:50 PM2:54 PM3:59 PM10.83

About Vir Biotechnology, Inc.

https://www.vir.bio ↗

Vir Biotechnology, Inc. is a San Francisco-based immunology company developing therapeutics and prevention products for infectious diseases like COVID-19, hepatitis B, influenza, and HIV through collaborations, licensing, and manufacturing agreeme...

INDUSTRY

Biotechnology

A PRODUCT VIR BIOTECHNOLOGY, INC. IS KNOWN FOR

Tobevibart and Elebsiran
Tobevibart and Elebsiran

Vir's leading investigational combination therapy for chronic hepatitis delta, in late-stage Phase 3 trials and FDA Breakthrough Therapy designation, is their most advanced candidate and central to their corporate strategy.

COMPETITORS

COMPETITOR
ABUS COMPARE
ALNY COMPARE
ARWR COMPARE
GILD COMPARE
IONS COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
License And Collaboration Revenue— — -$41K $238.94M ▲
Grant$305K $310K ▲$12K ▼$11K ▼
Collaboration Revenue-$65K — — —

Revenue by Geography

MapREGIONQ3-2025Q4-2025Q1-2026Q2-2026
UNITED STATES$305K $310K ▲$12K ▼$239.28M ▲
NonUS-$65K $60.94M ▲-$41K ▼-$341K ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
180
LISTED HERE
26
RANKED BY POSITION SIZE
XAW.TO
0.00% · 7.4M
XBI
0.50% · 5.3M
VTI
0.00% · 4.8M
SCHA
0.03% · 572.3K
FESM
0.10% · 554.8K
DFAS
0.04% · 535.6K
JMEE
0.17% · 439.5K
AVSC
0.11% · 310.5K
PRFZ
0.08% · 208.8K
LABU
0.34% · 191.7K
XRSG.L
0.04% · 112.5K
GNOM
0.97% · 82.3K
BBC
0.79% · 36.4K
GERM
2.79% · 29.9K
SILX
3.33% · 25.7K
NIXT
0.45% · 18.1K
RTWP.L
0.06% · 11.7K
ZSML.TO
0.07% · 11.7K
TILT
0.01% · 10.9K
RFLR
0.07% · 6.6K
BIB
0.06% · 6.0K
WCEO
0.21% · 2.5K
VIRS
0.10% · 2.3K
MOM
0.95% · 780
AESL
0.38% · 664
JHMH
0.05% · 602

INSTITUTIONAL OWNERSHIP

SHARES OWNED
69.40%
HOLDERS
351
TOP 12 OF 351 · RANKED BY POSITION SIZE
Blackrock, Inc.
20.7M sh · $210.71M
Sb Investment Advisers (Uk) Ltd
16.7M sh · $95.27M
Blackrock Inc.
16.4M sh · $146.26M
Arch Venture Management, LLC
12.9M sh · $115.73M
Vanguard Group Inc
12.8M sh · $73.08M
State Street Corp
10.0M sh · $101.53M
Gsk Plc
8.6M sh · $87.13M
Point72 Asset Management, L.P.
5.7M sh · $57.74M
Fmr LLC
3.6M sh · $20.77M
Geode Capital Management, LLC
3.3M sh · $34.12M
Goldman Sachs Group Inc
3.3M sh · $29.12M
Dimensional Fund Advisors LP
3.1M sh · $31.79M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
DIRECTOR
MORE ROBERT J
Purchase · 8.0K shares
2026-08-11
★
DIRECTOR
Coughlin Timothy
Purchase · 8.0K shares
2026-06-09
★
DIRECTOR
Coughlin Timothy
Purchase · 16.0K shares
2026-06-09
★
DIRECTOR
Coughlin Timothy
— · —
2026-06-09

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OVERWEIGHT 2
OUTPERFORM 2
BUY 2
6 GRADES IN THE LAST 12 MONTHS
Morgan Stanley OVERWEIGHT Leerink Partners OUTPERFORM HC Wainwright & Co. BUY Barclays OVERWEIGHT Evercore ISI Group OUTPERFORM Needham BUY

SECTORS PEERS

PEERPRICE
IOVA$8.01COMPARE
REPL$15.50COMPARE
KURA$12.66COMPARE
MRVI$7.68COMPARE
GERN$1.51COMPARE
PRME$3.61COMPARE
DNA$6.96COMPARE
YDES$4.80COMPARE